Multimodality treatment in immunocompromised patients with severe COVID‐19: the role of IL‐6 inhibitor, intravenous immunoglobulin, and haemoperfusion

Cytokine release syndrome (CRS) is known to be associated with severe coronavirus disease 2019 (COVID‐19). Multiple anti‐inflammatory therapies such as tocilizumab, corticosteroids, intravenous immunoglobulin (IVIG), and haemoadsorption or haemoperfusion have been used to combat this life‐threatenin...

Descripción completa

Detalles Bibliográficos
Autores principales: Leelayuwatanakul, Nophol, Kongpolprom, Napplika, Sriprasart, Thitiwat, Phoophiboon, Vorakamol, Thanthitaweewat, Vorawut, Thawanaphong, Sarita, Sirichana, Worawan, Chirakalwasan, Naricha, Kawkitinarong, Kamon, Sittipunt, Chanchai, Putcharoen, Opass, Paitoonpong, Leilani, Suwanpimolkul, Gompol, Jantarabenjakul, Watsamon, Srisawat, Nattachai, Pachinburavan, Monvasi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938208/
https://www.ncbi.nlm.nih.gov/pubmed/33732466
http://dx.doi.org/10.1002/rcr2.733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938208/
https://www.ncbi.nlm.nih.gov/pubmed/33732466
http://dx.doi.org/10.1002/rcr2.733

Ejemplares similares